Amedisys (NASDAQ: AMED) reported Q3 EPS of $1.00, $0.17 worse than the analyst estimate of $1.17. Revenue for the quarter came in at $587.7 million versus the consensus estimate of $589.39 million.

For earnings history and earnings-related data on Amedisys (AMED) click here.